PDF下载 ( 30584 KB)
黄芪甲苷Ⅳ对四氯化碳诱导的肝纤维化小鼠模型的影响及其作用机制
DOI: 10.12449/JCH260316
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：朱宛春进行实验和文章撰写；邱嘉昊、崔钰、张伊婧负责数据收集和统计分析；尚志负责技术支持和文章修改；黄凌鹰、高月求指导撰写文章并最后定稿。
Effect of astragaloside Ⅳ on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism
-
摘要:
目的 明确黄芪甲苷Ⅳ（AS-Ⅳ）在体内外的肝脏保护和抗肝纤维化作用，并探讨其在抗肝纤维化中的作用机制。 方法 动物实验：将C57BL/6J小鼠分为对照组、模型组、AS-Ⅳ低剂量组（20 mg/kg）和AS-Ⅳ高剂量组（80 mg/kg）。通过腹腔注射四氯化碳6周构建肝纤维化模型，从第3周开始，AS-Ⅳ组分别予以AS-Ⅳ 20 mg/kg、80 mg/kg灌胃，给药4周后检测血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）水平，以及血清透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PⅢNP）及Ⅳ型胶原（Col-Ⅳ）水平；苏木精-伊红染色、天狼星红染色和马松染色观察肝组织病理及胶原沉积情况；定量逆转录聚合酶链反应检测肝组织Acta2、Col1a1、Col3a1的mRNA表达；Western Blot法检测肝组织α-平滑肌肌动蛋白（α-SMA）、Ⅲ型胶原蛋白（Col-Ⅲ）、磷酸化磷脂酰肌醇3-激酶（pPI3K）/PI3K、磷酸化蛋白激酶B（pAkt）/Akt蛋白表达水平；运用转录组学技术对小鼠肝组织进行测序分析，筛选差异基因并进行生物信息学分析。细胞实验：采用转化生长因子β（TGF-β）诱导LX-2细胞活化，进一步使用PI3K抑制剂LY294002以及PI3K激动剂740 Y-P对细胞进行干预，设对照组、模型组、AS-Ⅳ组、LY294002组、AS-Ⅳ+740 Y-P组，36 h后收集细胞。检测LX-2细胞α-SMA、Col-Ⅲ、pPI3K/PI3K和pAkt/Akt蛋白表达的变化，以及Acta2、Col1a1和Col3a1的mRNA相对表达量。计量资料多组间比较采用单因素方差分析，进一步两两比较使用LSD-t检验。 结果 动物实验：与模型组相比，AS-Ⅳ治疗组小鼠血清ALT、AST、HA、LN、PⅢNP和Col-Ⅳ水平均显著降低（P值均<0.01）；肝组织Acta2、Col1a1和Col3a1的mRNA表达均显著降低（P值均<0.05）；与模型组相比，治疗组小鼠肝组织α-SMA、Col-Ⅲ、pPI3K和pAkt（Ser473）的蛋白表达均显著减少（P值均<0.05）。细胞实验：与对照组相比，TGF-β诱导后模型组细胞α-SMA、Col-Ⅲ、pPI3K和pAkt蛋白表达水平显著升高（P值均<0.05）；与模型组比较，AS-Ⅳ组细胞α-SMA、Col-Ⅲ、pPI3K和pAkt（Ser473）蛋白表达水平显著降低（P值均<0.05），LY294002组细胞pPI3K蛋白表达，以及Acta2、Col1a1和Col3a1的mRNA相对表达量亦显著降低（P值均<0.05）。而予740 Y-P干预后，与AS-Ⅳ组相比，pPI3K蛋白表达及Acta2、Col1a1和Col3a1的mRNA相对表达量均明显升高（P值均<0.05）。 结论 AS-Ⅳ通过抑制肝星状细胞活化从而改善肝纤维化，其作用机制可能与抑制PI3K/Akt信号通路有关。 -
关键词:
- 肝纤维化 /
- 黄芪甲苷Ⅳ /
- 小鼠， 近交C57BL /
- 肝星状细胞
Abstract:Objective To investigate the liver-protecting and anti-liver fibrosis effects of astragaloside Ⅳ （AS-Ⅳ） in vitro and in vivo， as well as its mechanism of action in intervention against liver fibrosis. Methods In the animal experiment， C57BL/6J mice were divided into control group， model group， low-dose AS-Ⅳ （20 mg/kg） group， and high-dose AS-Ⅳ （80 mg/kg） group. The mice were given intraperitoneal injection of carbon tetrachloride for 6 weeks to induce liver fibrosis， and since week 3 of injection， the mice in the low-dose AS-Ⅳ group and the high-dose AS-Ⅳ group were given AS-Ⅳ by gavage at a dose of 20 mg/kg and 80 mg/kg， respectively. The serum levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） were measured after 4 weeks of administration， as well as the serum levels of hyaluronic acid （HA）， laminin （LN）， procollagen Ⅲ N-terminal peptide （PⅢNP）， and collagen type Ⅳ （Col-Ⅳ）. HE staining， picrosirius red staining， and Masson staining were used to observe liver histopathology and collagen deposition； RT-qPCR was used to measure the mRNA expression levels of Acta2， Col1a1， and Col3a1 in liver tissue， and Western blot was used to measure the protein expression levels of α-smooth muscle actin （α-SMA）， collagen type Ⅲ （Col-Ⅲ）， phosphatidylinositol 3-kinase （PI3K）， phosphorylated PI3K （pPI3K）， protein kinase B （Akt）， and phosphorylated AKT （p-Akt） in liver tissue； transcriptome sequencing was performed for liver tissue to identify differentially expressed genes and perform a bioinformatics analysis. In the cell experiment， transforming growth factor-β （TGF-β） was used to induce the activation of LX-2 cells， and the PI3K inhibitor LY294002 and the PI3K activator 740 Y-P were used for intervention. The cells were divided into control group， model group， AS-Ⅳ group， LY294002 group， and AS-Ⅳ+740 Y-P group， and the cells were harvested after 36 hours of intervention. Changes in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K/PI3K， and pAkt/Akt in LX-2 cells were measured， as well as changes in the relative mRNA expression levels of Acta2， Col1a1， and Col3a1. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results In the animal experiment， compared with the model group， the AS-Ⅳ treatment group had significant reductions in the serum levels of ALT， AST， HA， LN， PⅢNP， and Col-Ⅳ （all P<0.01）， the mRNA expression levels of Acta2， Col1a1， and Col3a1 in liver tissue （all P<0.05）， and the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） in liver tissue （all P<0.05）. In the cell experiment， compared with the control group， the model group had significant increases in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） after TGF-β induction （all P<0.05）； compared with the model group， the AS-Ⅳ group had significant reductions in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） （all P<0.05）， and both the AS-Ⅳ group and the LY294002 group had significant reductions in the protein expression level of pPI3K and the relative mRNA expression levels of Acta2， Col1a1， and Col3a1 （all P<0.05）. Compared with the AS-Ⅳ group， there were significant increases in the protein expression level of pPI3K and the relative mRNA expression levels of Acta2， col1a1， and Col3a1 after 740 Y-P intervention （all P<0.05）. Conclusion AS-Ⅳ can inhibit hepatic stellate cell activation and improve liver fibrosis， possibly by inhibiting the PI3K/Akt signaling pathway. -
Key words:
- Hepatic Fibrosis /
- Astragaloside Ⅳ /
- Mice， Inbred C57BL /
- Hepatic Stellate Cells
-
注： a，血清ALT、AST水平；b，HE染色（×400）。ALT，丙氨酸氨基转移酶；AST，天冬氨酸氨基转移酶；AS-Ⅳ，黄芪甲苷Ⅳ；HE，苏木精-伊红。
图 1 AS-Ⅳ改善CCl4诱导的小鼠肝脏炎症
Figure 1. AS-Ⅳ attenuates inflammation in mice treated with CCl4
注： a，染色结果；b，小鼠血清HA、LN、PⅢNP、Col-Ⅳ水平。AS-Ⅳ，黄芪甲苷Ⅳ；HA，透明质酸；LN，层粘连蛋白；Col-Ⅳ，Ⅳ型胶原；PⅢNP，Ⅲ型前胶原。
图 2 AS-Ⅳ改善小鼠肝脏胶原沉积
Figure 2. AS-Ⅳ attenuates hepatic collagen deposition in mice
注： a，α-SMA、Col-Ⅲ的蛋白表达；b，Acta2、Col1a1、Col3a1的mRNA表达。AS-Ⅳ，黄芪甲苷Ⅳ；Col-Ⅲ，Ⅲ型胶原蛋白；α-SMA，α-平滑肌肌动蛋白；HSC，肝星状细胞。
图 3 AS-Ⅳ抑制小鼠肝脏HSC活化
Figure 3. AS-Ⅳ attenuates the activation of HSC in the mouse liver
注： a，差异表达基因火山图；b，差异表达基因聚类分析热图。
图 4 小鼠肝脏转录组测序分析
Figure 4. Mouse liver transcriptome sequencing analysis
注： a～c，生物过程、分子功能及细胞组分的GO富集分析；d，KEGG通路富集结果。GTP，鸟苷三磷酸；ATP，腺嘌呤核苷三磷酸；PI3K/Akt，磷脂酰肌醇3-激酶/蛋白激酶B；EGFR，表皮生长因子受体；ECM，细胞外基质。
图 5 功能富集分析和信号通路分析
Figure 5. Functional annotation and pathway enrichment analysis of differentially expressed genes
注： PI3K，磷脂酰肌醇3-激酶；pPI3K，磷酸化PI3K；Akt，蛋白激酶B；pAkt，磷酸化Akt；AS-Ⅳ，黄芪甲苷Ⅳ。
图 6 AS-Ⅳ对小鼠肝脏PI3K/Akt通路活化的影响
Figure 6. Effect of AS-Ⅳ on the activation of the PI3K/Akt pathway in the mouse liver
注： a，LX-2细胞中α-SMA、Col-Ⅲ的蛋白表达；b，LX-2细胞中PI3K、pPI3K、Akt、pAkt的蛋白表达；c，CCK-8检测AS-Ⅳ对LX-2细胞存活率的影响。AS-Ⅳ，黄芪甲苷Ⅳ；Col-Ⅲ，Ⅲ型胶原蛋白；α-SMA，α-平滑肌肌动蛋白；PI3K，磷脂酰肌醇3-激酶；pPI3K，磷酸化PI3K；Akt，蛋白激酶B；pAkt，磷酸化Akt；HSC，肝星状细胞；CCK-8，细胞计数试剂盒-8。
图 7 AS-Ⅳ对HSC激活的影响
Figure 7. Effect of AS-Ⅳ on HSC activation
注： a、c，LX-2细胞中PI3K、pPI3K的蛋白表达；b、d，LX-2细胞中Acta2、Col1a1、Col3a1的mRNA表达。AS-Ⅳ，黄芪甲苷Ⅳ；HSC，肝星状细胞；PI3K，磷脂酰肌醇3-激酶；pPI3K，磷酸化PI3K；Akt，蛋白激酶B。
图 8 AS-Ⅳ通过调控PI3K/Akt通路抑制HSC激活
Figure 8. AS-Ⅳ activates hepatic stellate cells through the PI3K/Akt pathway
表 表１ 引物序列
Table 表１. Primer sequences
基因 正向（5'-3'） 反向（5'-3'） Col3a1 小鼠肝组织 CTGTAACATGGAAACTGGGGAAA CCATAGCTGAACTGAAAACCACC 人LX-2细胞 CGTGGTAGCCCTGGTGAGAGAG TGGAGAACCGCTGGGACCTG Col1a1 小鼠肝组织 CAGGCTGGTGTGATGGGATT CGTTCTCCGCTCTCTCCAAA 人LX-2细胞 GAGGGCCAAGACGAAGACATC CAGATCACGTCATCGCACAAC Acta2 小鼠肝组织 TATCCCCGGGACTAAGACGG CTGTAGTCCCCCACTACCAC 人LX-2细胞 CTCTGGACGCACAACTGGCATC CCCATCAGGCAACTCGTAACTCTTC GAPDH 小鼠肝组织 AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 人LX-2细胞 GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
下载: 导出CSV
-
[1] HUANG DQ, TERRAULT NA, TACKE F, et al. Global epidemiology of cirrhosis: Aetiology, trends and predictions[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 6): 388- 398. DOI: 10.1038/s41575-023-00759-2. [2] ZHANG CY, LIU S, YANG M. Treatment of liver fibrosis: Past, current, and future[J]. World J Hepatol, 2023, 15( 6): 755- 774. DOI: 10.4254/wjh.v15.i6.755. [3] TRIVEDI P, WANG S, FRIEDMAN SL. The power of plasticity-metabolic regulation of hepatic stellate cells[J]. Cell Metab, 2021, 33( 2): 242- 257. DOI: 10.1016/j.cmet.2020.10.026. [4] YIN CY, EVASON KJ, ASAHINA K, et al. Hepatic stellate cells in liver development, regeneration, and cancer[J]. J Clin Invest, 2013, 123( 5): 1902- 1910. DOI: 10.1172/JCI66369. [5] ZHANG JQ, WU CX, GAO L, et al. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects[J]. Adv Pharmacol, 2020, 87: 89- 112. DOI: 10.1016/bs.apha.2019.08.002. [6] HUANG SW, SHAO XH, ZHANG X, et al. Effects of astragaloside IV on low-glucose mediated tumor immunosuppression microenvironment and its mechanism[J]. Chin J Clin Pharmacol Ther, 2024, 29( 11): 1201- 1211. DOI: 10.12092/j.issn.1009-2501.2024.11.001.黄仕文, 邵晓寒, 张雪, 等. 黄芪甲苷Ⅳ干预低糖介导的肿瘤免疫抑制微环境作用及其机制研究[J]. 中国临床药理学与治疗学, 2024, 29( 11): 1201- 1211. DOI: 10.12092/j.issn.1009-2501.2024.11.001. [7] LIANG XY, HONG FF, YANG SL. Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes, 2021, 14: 1871- 1883. DOI: 10.2147/DMSO.S304817. [8] ZHANG C, LI LL, HOU S, et al. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways[J]. J Ethnopharmacol, 2021, 279: 114350. DOI: 10.1016/j.jep.2021.114350. [9] CHEN HX, CAI JY, WANG JC, et al. Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation[J]. J Hepatol, 2021, 74( 5): 1176- 1187. DOI: 10.1016/j.jhep.2020.11.016. [10] YAN MY, CUI YM, XIANG Q. Metabolism of hepatic stellate cells in chronic liver diseases: Emerging molecular and therapeutic interventions[J]. Theranostics, 2025, 15( 5): 1715- 1740. DOI: 10.7150/thno.106597. [11] SUN YX, YUAN XY, HU ZH, et al. Harnessing nuclear receptors to modulate hepatic stellate cell activation for liver fibrosis resolution[J]. Biochem Pharmacol, 2025, 232: 116730. DOI: 10.1016/j.bcp.2024.116730. [12] HUANG FJ, XIE XX, LIU X, et al. Research progress on the active ingredients of traditional Chinese medicine against hepatic fibrosis by regulating the MAPK signaling pathway[J]. Chin J Hosp Pharm, 2025, 45( 2): 225- 233. DOI: 10.13286/j.1001-5213.2025.02.17.黄甫静, 谢星星, 刘学, 等. 中药活性成分调控MAPK信号通路抗肝纤维化的研究进展[J]. 中国医院药学杂志, 2025, 45( 2): 225- 233. DOI: 10.13286/j.1001-5213.2025.02.17. [13] CHEN SP, KANG RD, HONG XB, et al. Astragaloside IV regulates Snail1 lactylation and acetylation to mediate macrophage polarization and improve myocardial infarction[J]. Chin J Cell Mol Immunol, 2025, 41( 4): 289- 299. DOI: 10.13423/j.cnki.cjcmi.009952.陈少鹏, 康儒典, 洪新宝, 等. 黄芪甲苷Ⅳ调控Snail1乳酸化和乙酰化介导巨噬细胞极化改善大鼠心肌梗死[J]. 细胞与分子免疫学杂志, 2025, 41( 4): 289- 299. DOI: 10.13423/j.cnki.cjcmi.009952. [14] LI HL, WANG P, HUANG F, et al. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice[J]. Toxicol Appl Pharmacol, 2018, 340: 58- 66. DOI: 10.1016/j.taap.2017.12.019. [15] QING LY, LIU LT, XU QP, et al. Astragaloside IV attenuates pathological myocardial hypertrophy and fibrosis in mice via EGR1-SIRT1-PPARα-SCAD signaling pathway[J]. Chin Pharmacol Bull, 2025, 41( 2): 242- 250. DOI: 10.12360/CPB202406092.卿丽媛, 刘兰婷, 徐庆萍, 等. 黄芪甲苷Ⅳ基于EGR1-SIRT1-PPARα-SCAD信号通路减轻小鼠病理性心肌肥厚及纤维化[J]. 中国药理学通报, 2025, 41( 2): 242- 250. DOI: 10.12360/CPB202406092. [16] SHAMSAN E, ALMEZGAGI M, GAMAH M, et al. The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: A comprehensive review[J]. Front Med, 2024, 11: 1389329. DOI: 10.3389/fmed.2024.1389329. [17] WU C, HUANG L, MO LQ, et al. Anti-fibrotic effects of salvianolate on hepatic fibrosis in rats by regulating TGF-β1/Smad and PI3K/AKT/mTOR signaling pathway[J]. Chin J Hosp Pharm, 2019, 39( 7): 670- 675. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.07.04.吴灿, 黄亮, 莫立乾, 等. 丹参多酚酸盐通过TGF-β1/Smad和PI3K/AKT/mTOR信号通路抑制大鼠肝纤维化的进展[J]. 中国医院药学杂志, 2019, 39( 7): 670- 675. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.07.04. [18] WEI LW, CHEN QS, GUO AJ, et al. Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways[J]. Int Immunopharmacol, 2018, 60: 1- 8. DOI: 10.1016/j.intimp.2018.04.016. [19] AKKıZ H, GIESELER RK, CANBAY A. Liver fibrosis: From basic science towards clinical progress, focusing on the central role of hepatic stellate cells[J]. Int J Mol Sci, 2024, 25( 14): 7873. DOI: 10.3390/ijms25147873. [20] BAI XY, ZHANG X, HAI L, et al. Regulatory effect and mechanism of macrophage polarization in liver fibrosis[J]. J Clin Hepatol, 2024, 40( 3): 611- 615. DOI: 10.12449/JCH240329.白小洋, 张旭, 海龙, 等. 巨噬细胞极化在肝纤维化中的调控作用机制[J]. 临床肝胆病杂志, 2024, 40( 3): 611- 615. DOI: 10.12449/JCH240329. [21] GAO YY, ZHAN XY, ZHOU HM. The role of endoplasmic reticulum stress in regulating macrophage immune response in liver diseases[J]. Organ Transpl, 2024, 15( 6): 889- 894. DOI: 10.3969/j.issn.1674-7445.2024144.高逸云, 詹欣雨, 周浩明. 内质网应激调控巨噬细胞免疫应答在肝脏疾病中的作用[J]. 器官移植, 2024, 15( 6): 889- 894. DOI: 10.3969/j.issn.1674-7445.2024144. [22] WANG LP, HUANG Y, CHEN JR, et al. Dynamic crosstalk between HSCs and liver microenvironment: Multicellular interactions in the regulation of liver fibrosis[J]. Front Cell Dev Biol, 2025, 13: 1635763. DOI: 10.3389/fcell.2025.1635763. [23] DUFFIELD JS, FORBES SJ, CONSTANDINOU CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair[J]. J Clin Invest, 2005, 115( 1): 56- 65. DOI: 10.1172/JCI22675. [24] FENG M, DING J, WANG M, et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution[J]. Int J Biol Sci, 2018, 14( 9): 1033- 1040. DOI: 10.7150/ijbs.25589. [25] NI J, HONG XD, JI K, et al. Influence of hepatitis B combined with hepatic fibrosis on endogenous and exogenous metabolism and therapeutic implications[J]. Chin J Clin Pharmacol Ther, 2024, 29( 8): 853- 860. DOI: 10.12092/j.issn.1009-2501.2024.08.002.倪姐, 洪小丹, 计可, 等. 乙肝合并肝纤维化对内外源性代谢的影响及治疗学启示[J]. 中国临床药理学与治疗学, 2024, 29( 8): 853- 860. DOI: 10.12092/j.issn.1009-2501.2024.08.002. [26] SUGIMOTO A, SAITO Y, WANG GX, et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3[J]. Nature, 2025, 640( 8059): 752- 761. DOI: 10.1038/s41586-025-08677-w. -
本文二维码
图(8) / 表(1)
计量
- 文章访问数: 14
- HTML全文浏览量: 3
- PDF下载量: 4
- 被引次数: 0
